Impact of geriatric factors on surgical and prognostic outcomes in elderly patients with soft-tissue sarcoma

Tsuda, Yusuke; Kobayashi, Eisuke; Hiruma, Toru; Iwata, Shintaro; Asano, Naofumi; Kawai, Akira; Chuman, Hirokazu; Ishii, Takeshi; Morioka, Hideo; Kobayashi, Hiroshi; Kawano, Hirotaka

doi:10.1093/jjco/hyx016

Cited by 20 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This exceptional study was excluded because the data cannot be adequately transformed. Finally, 12 eligible studies with 2695 patients were included in this meta-analysis [30][31][32][33][34][35][36][37][38][39][40][41]. There is no disagreement among the two investigators during the data extraction process.…”

Section: Searchmentioning

confidence: 99%

“…The main features of the 12 included studies are summarized in Table 1. In short, four studies were conducted in Europe (1 in UK and 3 in Denmark) [30,32,35,40], while the other eight were in Asia (6 in China and 2 in Japan) [31,33,34,[36][37][38][39][40][41]. The sample size ranged from 83 to 888, while the follow-up time ranged from 20.3 months to 19 years.…”

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

“…All the 12 included studies were retrospectively designed. Five studies focused on bone sarcoma patients [30,31,33,34,41], another five focused on soft tissue sarcoma patients [35][36][37][38][39], and the other two focused on both bone and soft tissue sarcoma patients [32,40]. Five of the 12 included studies declared that patients with medical conditions known to affect systemic inflammation status were excluded [31,33,34,36,38].…”

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

“…Eleven studies investigated the prognostic value of GPS for sarcoma patients. Seven of them reported the prognostic role of GPS for OS [30,31,33,34,36,38,39], four of them reported the prognostic role of GPS for DSS [30,32,35,40], and another four reported the prognostic role of GPS for DFS [32,[36][37][38]. Nine of the eleven studies evaluated traditional GPS, one [32] evaluated mGPS (modified GPS), two [36,37] evaluated Hs-mGPS (high sensitive modified GPS), and the other one [38] evaluated both traditional GPS and mGPS.…”

Section: The Characteristics Of the Included Studiesmentioning

confidence: 99%

“…The prognostic significance of GPS and CAR has also been investigated in sarcoma patients, and controversial results have also been reported [30][31][32][33][34][35][36][37][38][39][40][41][42]. To our knowledge, no system review or meta-analysis has been conducted on this subject for sarcoma.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Backgrounds. Both pretreatment serum CRP (C-reactive protein) level and ALB (albumin) level have been found to be predictive of survival for multiple malignancies including sarcoma. Since both of the GPS (Glasgow prognostic score) and CAR (C-reactive protein to albumin ratio) are based on the combination of CRP and ALB, we conducted a meta-analysis to evaluate the prognostic role of these two parameters for sarcoma patients. Methods. A detailed literature search was conducted in MEDLINE, Embase, and Cochrane Library for relevant research publications written in English. Patients' clinical characteristics, outcomes of overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were extracted. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were combined to evaluate the prognostic role of GPS or CAR. Results. Twelve articles containing 2695 patients were identified as eligible studies. The results showed that an elevated GPS was significantly correlated with poor OS (HR = 2:42; 95% CI: 1.98-2.94; p < 0:001; fixed-effects model), DSS (HR = 2:28; 95% CI: 1.75-2.97; p < 0:001; fixed-effects model), and DFS (HR = 2:05; 95% CI: 1.62-2.60; p < 0:001; fixed-effects model). A higher CAR also was shown to be significantly correlated with poor OS (HR = 2:23; 95% CI: 1.70-2.92; p < 0:001; fixed-effects model) and DFS (HR = 1:81; 95% CI: 1.7-2.58; p = 0:001; fixed-effects model). Conclusion. An elevated GPS is predictive of poor survival in patients with sarcomas and is promising to be used as a factor for risk stratification. A higher CAR value is also predictive of poor survival; however, the optimal CAR cut-off value is still to be determined.

show abstract